Share-based Payment Arrangement, Expense of Sagimet Biosciences Inc. from 30 Jun 2022 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Sagimet Biosciences Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2022 to 30 Sep 2025.
  • Sagimet Biosciences Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,688,000, a 9.2% increase year-over-year.
  • Sagimet Biosciences Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $6,292,000, a 24% increase year-over-year.
  • Sagimet Biosciences Inc. annual Share-based Payment Arrangement, Expense for 2024 was $5,288,000, a 6% increase from 2023.
  • Sagimet Biosciences Inc. annual Share-based Payment Arrangement, Expense for 2023 was $4,990,000, a 165% increase from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Sagimet Biosciences Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $6,292,000 $1,688,000 +$142,000 +9.2% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $6,150,000 $1,598,000 +$149,000 +10% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $6,001,000 $1,472,000 +$713,000 +94% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $5,288,000 $1,534,000 +$223,000 +17% 01 Oct 2024 31 Dec 2024 10-K 12 Mar 2025 2024 FY
Q3 2024 $5,065,000 $1,546,000 -$309,000 -17% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $5,374,000 $1,449,000 +$392,000 +37% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q1 2024 $4,982,000 $759,000 -$8,000 -1% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $4,990,000 $1,311,000 01 Oct 2023 31 Dec 2023 10-K 12 Mar 2025 2024 FY
Q3 2023 $1,855,000 +$1,466,000 +377% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $1,057,000 +$674,000 +176% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024 2024 Q2
Q1 2023 $767,000 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q3 2022 $389,000 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 $383,000 01 Apr 2022 30 Jun 2022 10-Q 21 Aug 2023 2023 Q2

Sagimet Biosciences Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $5,288,000 +$298,000 +6% 01 Jan 2024 31 Dec 2024 10-K 12 Mar 2025 2024 FY
2023 $4,990,000 +$3,110,000 +165% 01 Jan 2023 31 Dec 2023 10-K 12 Mar 2025 2024 FY
2022 $1,880,000 01 Jan 2022 31 Dec 2022 10-K 25 Mar 2024 2023 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.